Production (Stage)
Theravance Biopharma, Inc.
TBPH
$9.30
-$0.19-2.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -16.42% | -82.46% | -41.88% | -5.65% | 47.19% |
| Total Depreciation and Amortization | -10.05% | -18.96% | 16.36% | -5.16% | 56.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -33.84% | -107.97% | -2.84% | 6.33% | -34.33% |
| Change in Net Operating Assets | 1,161.22% | 506.77% | 74.57% | 145.86% | 79.90% |
| Cash from Operations | 4,311.25% | -5.62% | -109.01% | 64.50% | 90.89% |
| Capital Expenditure | -- | 71.94% | 28.57% | 95.77% | 90.30% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 78.94% | -- | -- | -128.27% | 140.45% |
| Cash from Investing | 79.89% | 2,416.99% | -82,752.38% | -127.44% | 139.56% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -5.78% | -- | -6.05% | -- |
| Repurchase of Common Stock | 49.07% | 98.28% | 98.74% | 99.43% | 96.95% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 50.23% | 98.81% | 98.82% | 99.95% | 96.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 409.57% | 144.86% | 32.27% | 90.87% | 112.93% |